Truly incredible!
This is nuts. Abdul El-Sayed’s h-index on Google Scholar is 37 — higher than that of your average tenured professor at an Ivy League school.View quoted post on X
Babur Lateef, MD
Verified account This account is verified. Learn more@LateefForVA
Husband, Father, Ophthalmologist, Current Chair of the Prince William County School Board. Youngstown born and raised. Tweets are all my own.
1.5K Following 3K Followers 3.5K Posts
Latest posts 5
.@NIHDirector_Jay highlighting the groundbreaking discovery in MS, ALS, and macular degeneration by @UVA @uvahealthnews research Dr Jay Ambati. New treatments are closer than they ever have been for some of the most difficult medical challenges we face.
🔬Traditional treatments for multiple sclerosis (MS) can help mitigate a patient’s symptoms or keep them from returning.
Now, new NIH-funded research suggests that a modified drug historically used for treating HIV and Hepatitis B could potentially reverse the disease’s effects.
Learn more ➡️ bit.ly/4rwr37xView quoted post on X
Incredible results from @UVA , @uvahealthnews research physician, Dr. Jay Ambati, and his team developing treatments for MS, ALS, macular degeneration, and other neurodegenerative diseases!
Congrats to the team @InflammasomeTx and strong work to revolutionize treatments for MS , ALS, macular degeneration and other neurodegenerative diseases!
Message to Americans living with multiple sclerosis (MS): There is Hope!View quoted post on X
Thanks to the groundbreaking research taking place under @POTUS' and @SecKennedy's leadership, a new study by the @NIH has found promising results in reversing pre-existing vision loss and paralysis in MS models.
Learn more 👇
Inflammation Matters⬇️⬇️⬇️
We’re honored to see Inflammasome Therapeutics highlighted by The New York Times Magazine in its exploration of chronic inflammation and the promise of targeting inflammasomes to treat diseases including geographic atrophy and ALS.View quoted post on X
The article discusses our programs for geographic atrophy and ALS and quotes our co-founder, Jayakrishna Ambati:
“This is something that could reach patients literally in the next 18 to 24 months.”
We are grateful to see this important area of science and its potential to translate into meaningful therapies for patients receive international attention.
Read the full article:
nytimes.com/interactive/20…
